Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CGON
Strong SellHot AirCG Oncology, Inc. · Healthcare · United States · $6.6B · Avg Vol: $51M/d
COMPANY DESCRIPTION
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies for cancer. Its lead candidate, cretostimogene grenadenorev, is designed to selectively replicate in and destroy cancer cells while stimulating an anti-tumor immune response. The company's potential competitive moat lies in its innovative oncolytic virus platform targeting specific cancer types, positioning it as a specialized player in the immuno-oncology space.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.2M | 0.2M | 1.1M | 4.0M | 176.6% | 6.2M | 4.5M | 95.6M | 386.5% |
| EPS | -11.71 | -15.65 | -1.41 | -2.08 | — | -2.69 | -3.20 | -3.02 | — |
| Shares | 63.5M | 63.5M | 76.2M | 80.7M | +27.1% | 88.6M | — | — | — |
| Debt | 15.9M | 0.5M | 0.2M | 7.0M | -23.9% | 8.8M | — | — | — |
| Equity | 125.2M | 184.8M | 733.4M | 752.6M | 81.8% | — | — | — | — |
| Op CF | -29.8M | -45.7M | -78.7M | -132.3M | — | -178.5M | — | — | — |
| Inv CF | -55.4M | -121.2M | -300.8M | -245.8M | — | — | — | — | — |
| Fin CF | 119.7M | 87.0M | 628.3M | 153.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CGON are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CGON | CG Oncology, Inc.(you) | $6.6B | 17 | Strong Sell |
| SRRK | Scholar Rock Holding Corporation | $7.0B | 19 | Strong Sell |
| ERAS | Erasca, Inc. | $6.3B | 14 | Strong Sell |
| COGT | Cogent Biosciences, Inc. | $6.0B | 12 | Strong Sell |
| DNTH | Dianthus Therapeutics, Inc. | $5.9B | 23 | Sell |
| DFTX | Definium Therapeutics, Inc. | $5.5B | 22 | Sell |
| IMVT | Immunovant, Inc. | $8.5B | 21 | Sell |
| SYRE | Spyre Therapeutics, Inc. | $8.0B | 23 | Sell |
| IBRX | ImmunityBio, Inc. | $8.5B | 22 | Sell |
| TNGX | Tango Therapeutics, Inc. | $3.9B | 17 | Strong Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%